查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1405863

流感治療市場規模、佔有率、趨勢分析報告：依治療藥物、給藥途徑、配銷通路、地區、細分市場預測，2024-2030年

Influenza Treatment Market Size, Share & Trends Analysis Report By Treatment (Peramivir, Zanamivir, Baloxavir Marboxil, Oseltamivir Phosphate), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10個工作天內

價格

流感治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球流感治療市場預計將達到64.4億美元，2024年至2030年複合年成長率為1.18%。

該市場的成長是由於流感盛行率的上升以及對治療該疾病的有效療法的需求不斷成長。此外，主要企業不斷致力於開發新的治療方法，以滿足對精準藥物治療不斷成長的需求，FDA 正在舉措核准流感治療藥物。因此，全球對治療的持續需求正在推動整體市場的成長。

此外，季節性流感和呼吸道疾病盛行率的上升也推動了對新療法的需求。據美國疾病管制與預防中心(CDC)稱，2010年至2020年間，美國流感造成的負擔估計為每年900萬至4100萬人患病、14萬至71萬人住院、12000至52000人死亡。預計這將導致。同樣，初步調查結果表明，從 2021 年到 2022 年，將有約 900 萬人報告出現症狀，約 400 萬人次就診，10 萬人住院治療，5,000 人死亡。

市場成長是由病毒感染疾病創新療法的持續核准和即將商業化所推動的。例如，2022年8月，羅氏宣布美國FDA核准Xofluza（baloxavir marboxil）用於治療5至12歲有症狀48小時兒童的急性流感。此外，該行業的領導者在過去2至3年內推出了多種治療病毒感染疾病的新藥，導致市場上其他小型企業佔據了很大的收益佔有率，這支持了對新藥開拓的需求。

此外，COVID-19大流行顯著促進了市場成長。在大流行期間，有效控制疾病的需要導致對抗新型冠狀病毒的廣譜抗病毒藥物的需求激增。瑞德西韋、法匹拉韋、奧司他韋和各種聯合治療藥物已被廣泛用於治療 COVID-19。此外，政府正在向製藥公司分配更多資金，以加速針對 COVID-19 的新療法的開發。例如，2021年6月，美國政府宣布投資超過30億美元，加速抗病毒藥物的發現、製造和開發。隨著發病率持續上升以及研發工作的加強，預計未來兩到三年抗病毒藥物的需求將會增加。

此外，主要參與企業正在採取各種策略，例如產品發布、聯盟/合作和併購，以擴大其國際足跡並保持在流感治療市場的競爭地位。例如，2020年11月，鹽野義的XOFLUZA（Baloxavir Marboxil）獲得FDA核准作為流感預防藥物。同樣，2021年2月，FDA擴大了對BioCryst Pharmaceuticals的產品帕拉米韋注射液Rapivab的核准。本產品廣泛用於治療 6 個月以上、出現症狀兩天的患者的急性、無併發症的流感。

流感治療藥物市場報告亮點

  • 以治療藥物來看，2023年磷酸奧司他韋製劑佔市場最大銷售佔有率。
  • 從給藥途徑來看，由於給藥方便，口服藥物的採用正在增加，就2023年的銷售佔有率而言，口服藥物在市場上佔據主導地位。
  • 按配銷通路，由於住院患者數量增加以及醫院藥房配藥的利用率增加，醫院藥房細分市場將在 2023 年佔據主導地位。
  • 由於老字型大小企業的存在、季節性流感疫情的增加以及流感導致的住院人數的增加，北美在 2023 年佔據了最大的佔有率。

目錄

第1章流感治療市場：調查方法與範圍

第2章流感治療市場：執行摘要

  • 市場概述
  • 治療概況及給藥途徑
  • 配銷通路簡介
  • 競爭形勢概覽

第3章流感治療市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
  • 市場促進因素分析
    • 更多 FDA核准的新流感藥物
    • 流感等傳染性呼吸道疾病的傳播；
  • 市場抑制因素分析
    • 與流感治療相關的複雜症狀
  • 波特五力分析
  • PESTLE分析

第4章流感治療市場：治療估計與趨勢分析

  • 流感治療市場：治療變異分析
  • 帕拉米韋
    • 2018-2030 年帕拉米韋市場估計與預測
  • 扎那米韋
    • 扎那米韋市場估計與預測，2018-2030
  • 巴洛沙韋酯
    • Baloxavir marboxil 市場估計與預測，2018-2030
  • 磷酸奧司他韋
    • 2018-2030年磷酸奧司他韋市場估計與預測
  • 其他
    • 2018-2030 年其他市場估計與預測

第5章流感治療市場：給藥途徑預估及趨勢分析

  • 流感藥物市場：給藥變化分析
  • 口服
    • 2018-2030 年口腔市場估計與預測
  • 其他
    • 2018-2030 年其他市場估計與預測

第6章 流感治療藥物市場：配銷通路估算及趨勢分析

  • 流感治療藥物市場：配銷通路波動分析
  • 醫院藥房
    • 2018-2030 年醫院藥局市場估計與預測
  • 零售藥房
    • 2018-2030 年零售藥局市場估計與預測
  • 網路藥房
    • 2018-2030 年線上藥局市場估計與預測

第7章流感治療市場：區域業務分析

  • 區域市場簡介
  • 北美洲
    • 2018-2030 年北美流感治療市場估計與預測
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲流感治療市場，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 挪威
    • 瑞典
  • 亞太地區
    • 亞太地區流感治療市場，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 拉丁美洲流感治療市場，2018-2030
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 中東和非洲流感治療市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭形勢

  • 公司分類
  • 策略規劃
    • 新推出
    • 合夥
    • 獲得
    • 合作
  • 2023年主要企業市場佔有率分析
  • 企業熱力圖分析
  • 公司簡介
    • Natco Pharma Limited
    • Novartis Ag
    • F. Hoffmann-la Roche Ltd
    • Biocryst Pharmaceuticals, Inc.
    • Sanofi
    • Gsk Plc.
    • Viatris Inc.（Mylan）
    • Teva Pharmaceutical Industries Ltd.
    • Daiichi Sankyo Company, Limited.
    • Astrazeneca
Product Code: GVR-4-68040-168-6

Influenza Treatment Market Growth & Trends:

The global influenza treatment market is expected to reach USD 6.44 billion by 2030, expanding at a CAGR of 1.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is attributed to the rising prevalence of influenza aided by the rising need for efficient therapeutics to treat the condition. Furthermore, key players are constantly focusing on developing novel therapeutics to meet the rising demand for precise medication with constant initiative by the FDA for approval of influenza treatment drugs. As a result of which, the constant demand for treatment globally is fueling the growth of the overall market.

Additionally, the rising prevalence of seasonal flu and respiratory diseases has boosted the demand for novel therapeutics. According to CDC, it is estimated that the burden of flu in the U.S. had resulted in 9 million -41 million illnesses, 140,000 - 710,000 hospitalizations, and 12,000 - 52,000 deaths yearly between 2010 and 2020. Similarly, according to preliminary results around 9 million individuals had symptomatic illnesses, and approximately 4 million medical visits, 100,000 hospitalizations, and 5 thousand deaths were reported from 2021 to 2022.

The market growth is expected to be driven by the increasing approval and upcoming commercialization of innovative medications for viral infections. For instance, in August 2022, Roche announced the U.S. FDA approval for Xofluza (baloxavir marboxil), used for the treatment of acute influenza in children aged 5 to 12 years who have been symptomatic for 48 hours. Additionally, prominent players in the industry have introduced several novel medicines for viral infections within the span of 2 to 3 years propelling the need for the development of novel medication by other small players operating in the market in order to generate significant revenue share.

Moreover, the COVID-19 pandemic has significantly boosted the growth of the market. During the pandemic, the demand for broad-spectrum antiviral drugs to combat the novel coronavirus has surged due to the need to manage the disease effectively. Medications like Remdesivir, favipiravir, oseltamivir, and various combination therapies have become widely prescribed for treating COVID-19. Additionally, governments are allocating greater funding to pharmaceutical companies to expedite the development of novel therapeutics against COVID-19. For instance, in June 2021, the U.S. government announced an investment of over USD 3 billion to accelerate the discovery, manufacturing, and development of antiviral medicines. As the incidence of the disease continues to rise and research and development efforts intensify, the demand for antiviral drugs is expected to increase in the next 2 to 3 years.

Furthermore, the key participants are engaged in various strategies such as product launches, partnerships & collaborations, and mergers & acquisitions, to expand their global footprints and maintain their competitive position in the influenza treatment market. For instance, in November 2020, Shionogi's XOFLUZA (Baloxavir Marboxil) received FDA approval for the prevention of influenza. Similarly, in February 2021, FDA expanded the approval of Rapivab which is a peramivir injection, a product of BioCryst Pharmaceuticals. The product is extensively used for treating acute uncomplicated influenza in 6 months of age & older patients who have been symptomatic for 2 days.

Influenza Treatment Market Report Highlights:

  • Based on treatment, the oseltamivir phosphate segment held the largest revenue share in 2023 in the market owing to the rising prevalence of influenza leading to increasing prescription of oseltamivir phosphate
  • Based on route of administration, the oral segment dominated the market with a revenue share in 2023 attributed to the increased adoption of oral drug products due to their ease of administration
  • On the basis of distribution channel, the hospital pharmacy segment dominated the market in 2023 due to the rising hospitalization and use of hospital pharmacies for medication
  • North America held the largest share in 2023 owing to the presence of well-established players, the rising prevalence of seasonal flu, and an increased hospitalization due to the condition

Table of Contents

Chapter 1. Influenza Treatment Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Influenza Treatment Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Treatment and Route of Administration Snapshot
  • 2.3. Distribution Channel Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Influenza Treatment Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Rising new FDA-approved influenza treatment drugs
    • 3.4.2. Prevalence of contagious respiratory illness such as influenza
  • 3.5. Market Restraint Analysis
    • 3.5.1. Complicated conditions associated with influenza treatment
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. Influenza Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Influenza Treatment Market: Treatment Movement Analysis
  • 4.2. Peramivir
    • 4.2.1. Peramivir Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Zanamivir
    • 4.3.1. Zanamivir Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Baloxavir Marboxil
    • 4.4.1. Baloxavir Marboxil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Oseltamivir Phosphate
    • 4.5.1. Oseltamivir Phosphate Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Influenza Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Influenza Treatment Market: Route of Administration Movement Analysis
  • 5.2. Oral
    • 5.2.1. Oral Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3. Others
    • 5.3.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Influenza Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Influenza Treatment Market: Distribution Channel Movement Analysis
  • 6.2. Hospital Pharmacies
    • 6.2.1. Hospital Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacies
    • 6.3.1. Retail Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Online Pharmacies
    • 6.4.1. Online Pharmacies Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Influenza Treatment Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Influenza Treatment Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. France
      • 7.3.4.1. France Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. Italy
      • 7.3.5.1. Italy Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Spain
      • 7.3.6.1. Spain Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Norway
      • 7.3.8.1. Norway Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Sweden
      • 7.3.9.1. Sweden Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-pacific Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Australia
      • 7.4.6.1. Australia Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Mexico
      • 7.5.3.1. Mexico Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
    • 7.5.4. Argentina
      • 7.5.4.1. Argentina Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.5.4.2. Key Country Dynamics
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Scenario
      • 7.5.4.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Influenza Treatment Market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Influenza Treatment Market, 2018 - 2030 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New Launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
  • 8.3. Key Company Market Share Analysis, 2023
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. Natco Pharma Limited
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Novartis Ag
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-la Roche Ltd
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Biocryst Pharmaceuticals, Inc.
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Sanofi
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Gsk Plc.
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Viatris Inc. (Mylan)
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Teva Pharmaceutical Industries Ltd.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Daiichi Sankyo Company, Limited.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Astrazeneca
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Influenza Treatment Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 North America Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 5 North America Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 6 North America Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 North America Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 8 U.S. Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 U.S. Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 Canada Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Canada Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Europe Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 15 Europe Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 16 Europe Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 17 Europe Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 18 Germany Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 Germany Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 20 Germany Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 21 UK Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 22 UK Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 23 UK Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 France Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 France Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 26 France Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Spain Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 28 Spain Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 29 Spain Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 Italy Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Italy Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 32 Italy Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Denmark Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 34 Denmark Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 35 Denmark Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Norway Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 37 Norway Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 38 Norway Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Sweden Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 Sweden Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 41 Sweden Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 Japan Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 47 Japan Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 Japan Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 China Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 50 China Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 China Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 India Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 India Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 India Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Australia Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 56 Australia Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 Australia Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 South Korea Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 59 South Korea Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 South Korea Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Thailand Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 Thailand Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Thailand Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Latin America Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 65 Latin America Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 66 Latin America Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Latin America Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 68 Brazil Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 69 Brazil Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 71 Mexico Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 72 Mexico Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 73 Mexico Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 74 Argentina Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 75 Argentina Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 76 Argentina Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 77 Middle East & Africa Influenza Treatment Market, By Country, 2018 - 2030 (USD Million)
  • Table 78 Middle East & Africa Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 81 Saudi Arabia Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 84 South Africa Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Africa Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 86 South Africa Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 87 UAE Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 88 UAE Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 89 UAE Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Influenza Treatment Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 91 Kuwait Influenza Treatment Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Influenza Treatment Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global influenza treatment market- Key market driver analysis
  • Fig. 7 Global influenza treatment market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global influenza treatment market - Porter's analysis
  • Fig. 10 Global influenza treatment market - PESTEL analysis
  • Fig. 11 Global influenza treatment market: Treatment outlook key takeaways
  • Fig. 12 Global influenza treatment market: Treatment movement analysis
  • Fig. 13 Peramivir market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Zanamivir market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Baloxavir marboxil market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Oseltamivir phosphate market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Global influenza treatment market: Route of Administration outlook key takeaways
  • Fig. 19 Global influenza treatment market: Route of Administration movement analysis
  • Fig. 20 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Global influenza treatment market: Distribution Channel outlook key takeaways
  • Fig. 23 Global influenza treatment market: Distribution Channel movement analysis
  • Fig. 24 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Retail pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 Global influenza treatment market: Regional movement analysis
  • Fig. 29 North America influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 30 U.S. influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 32 Europe influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 UK influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 34 Germany influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 France influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 Italy influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 Spain influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Denmark influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Asia Pacific influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Japan influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 China influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 India influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Latin America influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 49 Brazil influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Mexico influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 51 Argentina influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 MEA influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 South Africa influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Saudi Arabia influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 UAE influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Kuwait influenza treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 Strategy framework